<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>All-trans retinoic acid (systemic tretinoin): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">All-trans retinoic acid (systemic tretinoin): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">All-trans retinoic acid (systemic tretinoin): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9262" href="/d/html/9262.html" rel="external">see "All-trans retinoic acid (systemic tretinoin): Drug information"</a> and <a class="drug drug_patient" data-topicid="11116" href="/d/html/11116.html" rel="external">see "All-trans retinoic acid (systemic tretinoin): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708896"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients with acute promyelocytic leukemia (APL) are at high risk in general and can have severe adverse reactions to tretinoin capsules. Tretinoin capsules should, therefore, be administered only to patients with APL under the strict supervision of a physician who is experienced in the management of patients with acute leukemia and in a facility with laboratory and supportive services sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity, including respiratory compromise. Use of tretinoin capsules requires that the physician concludes that the possible benefit to the patient outweighs the following known adverse reactions in therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Differentiation syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Approximately 25% of patients with APL treated with tretinoin capsules have experienced a syndrome called the retinoic acid-APL (RA-APL) syndrome, characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multiorgan failure. This syndrome occasionally has been accompanied by impaired myocardial contractility and episodic hypotension. It has been observed with or without concomitant leukocytosis. Endotracheal intubation and mechanical ventilation have been required in some cases due to progressive hypoxemia, and several patients have expired with multiorgan failure. The syndrome generally occurs during the first month of treatment, with some cases reported following the first dose of tretinoin capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">The management of the syndrome has not been defined rigorously, but high-dose steroids given at the first suspicion of the RA-APL syndrome appear to reduce morbidity and mortality. At the first signs suggestive of the syndrome (unexplained fever, dyspnea and/or weight gain, abnormal chest auscultatory findings, or radiographic abnormalities), high-dose steroids (dexamethasone 10 mg intravenously administered every 12 hours for 3 days or until the resolution of symptoms) should be immediately initiated, irrespective of the leukocyte count. The majority of patients do not require termination of tretinoin capsules therapy during treatment of the RA-APL syndrome. However, in cases of moderate and severe RA-APL syndrome, temporary interruption of tretinoin capsules therapy should be considered.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Leukocytosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">During tretinoin capsules treatment, about 40% of patients will develop rapidly evolving leukocytosis. Patients who present with high WBC at diagnosis (&gt;5 × 10<sup>9</sup>/L) have an increased risk of a further rapid increase in WBC. Rapidly evolving leukocytosis is associated with a higher risk of life-threatening complications.</p>
<p style="text-indent:-2em;margin-left:2em;">If signs and symptoms of the RA-APL syndrome are present together with leukocytosis, treatment with high-dose steroids should be initiated immediately. Some investigators routinely add chemotherapy to tretinoin capsules treatment in the case of patients presenting with a WBC of &gt;5 × 10<sup>9</sup>/L or in the case of a rapid increase in WBC for patients leukopenic at start of treatment, and have reported a lower incidence of the RA-APL syndrome. Consideration could be given to adding full-dose chemotherapy (including an anthracycline if not contraindicated) to the tretinoin capsules therapy on day 1 or 2 for patients presenting with a WBC of &gt;5 × 10<sup>9</sup>/L, or immediately, for patients presenting with a WBC of &lt;5 × 10<sup>9</sup>/L, if the WBC reaches ≥6 × 10<sup>9</sup>/L by day 5, or ≥10 × 10<sup>9</sup>/L by day 10, or ≥15 × 10<sup>9</sup>/L by day 28.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Pregnancy (Category D): There is a high risk that a severely deformed infant will result if tretinoin capsules are administered during pregnancy. If, nonetheless, it is determined that tretinoin capsules represent the best available treatment for a pregnant woman or a woman of childbearing potential, it must be assured that the patient has received full information and warnings of the risk to the fetus if she were to be pregnant and of the risk of possible contraception failure and has been instructed in the need to use 2 reliable forms of contraception simultaneously during therapy and for 1 month following discontinuation of therapy, and has acknowledged her understanding of the need for using dual contraception, unless abstinence is the chosen method.</p>
<p style="text-indent:-4em;margin-left:4em;">Within 1 week prior to the institution of tretinoin capsules therapy, the patient should have blood or urine collected for a serum or urine pregnancy test with a sensitivity of at least 50 milliunits/mL. When possible, tretinoin capsules therapy should be delayed until a negative result from this test is obtained. When a delay is not possible, the patient should be placed on 2 reliable forms of contraception. Pregnancy testing and contraception counseling should be repeated monthly throughout the period of tretinoin capsules treatment.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868490"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Tretinoin;</li>
<li>Vesanoid</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1040438"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Retinoic Acid Derivatives</span>;</li>
<li>
<span class="list-set-name">Retinoic Acid Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F230440"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Frequency, number of doses, timing of doses during cycles/phases, and concomitant therapy may vary; refer to individual protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f133373-607c-467b-8bff-de6df2e90e5c">Acute promyelocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia (APL):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288','lexi-content-ref-16234524','lexi-content-ref-30803991','lexi-content-ref-15677559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288','lexi-content-ref-16234524','lexi-content-ref-30803991','lexi-content-ref-15677559'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Daily doses should be rounded to the nearest 10 mg (ie, if &lt;5 mg round down; if ≥5 mg round up); if necessary, the morning dose may differ from the evening dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Remission induction</i>: Oral: 25 mg/m<sup>2</sup>/day in 2 divided doses days 1 to 30 (in combination with idarubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>). Induction treatment of APL with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RARα fusion protein.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation 1</i>: Oral: 25 mg/m<sup>2</sup>/day in 2 divided doses on days 1 to 14 of a 35-day cycle; repeat once for a total of 2 cycles (in combination with arsenic trioxide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation 2:</i> Oral: 25 mg/m<sup>2</sup>/day in 2 divided doses on days 1 to 14 (in combination with IV cytarabine [high-dose], intrathecal cytarabine, and mitoxantrone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation 3</i>: Oral: 25 mg/m<sup>2</sup>/day in 2 divided doses on days 1 to 14 (in combination with intrathecal cytarabine and idarubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation 4 (only for high-risk APL):</i> Oral: 25 mg/m<sup>2</sup>/day in 2 divided doses on days 1 to 14 (in combination with IV cytarabine [high-dose], intrathecal cytarabine, and idarubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i> Oral: 25 mg/m<sup>2</sup>/day in 2 divided doses on days 1 to 14 (in combination with oral methotrexate, mercaptopurine, and intrathecal cytarabine [first cycle only]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: Note: </b>Refer to specific protocol(s) for detailed information related to management for the following and other drug-related toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">APL differentiation syndrome: Hold tretinoin and initiate dexamethasone 0.25 mg/kg/dose (maximum dose: 10 mg) IV or orally every 12 hours for 3 days; resume tretinoin after resolution of signs/symptoms; if symptoms persistent longer than 3 days or recur with therapy, hold tretinoin therapy and evaluate case on an individual basis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767288'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F51192985"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51220264"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment: Based on experience in adult patients, liver enzymes may normalize with dosage reduction or with continued treatment; discontinue if normalization does not readily occur or if hepatitis is suspected.</p></div>
<div class="block doa drugH1Div" id="F230429"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9262" href="/d/html/9262.html" rel="external">see "All-trans retinoic acid (systemic tretinoin): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Acute promyelocytic leukemia (APL) induction treatment with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RARα fusion protein. In patients presenting with WBC ≥5,000/mm<sup>3 </sup>or serum creatinine &gt;1.39 mg/dL, consider systemic corticosteroids (eg, dexamethasone, prednisone) for prophylaxis of differentiation syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18945964','lexi-content-ref-31410848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18945964','lexi-content-ref-31410848'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f133373-607c-467b-8bff-de6df2e90e5c">Acute promyelocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Remission induction:</b></i>
<b>Note:</b> For non–high-risk APL patients (WBC ≤10,000/mm<sup>3</sup>), induction therapy consists of tretinoin with arsenic trioxide, although tretinoin with anthracycline-based chemotherapy is an option when arsenic trioxide cannot be used. For patients with high-risk APL (WBC &gt;10,000/mm<sup>3</sup>), induction therapy generally consists of tretinoin and anthracycline-based chemotherapy ± arsenic trioxide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30803991','lexi-content-ref-32171751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30803991','lexi-content-ref-32171751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Manufacturer's labeling: </i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses until documentation of complete remission (CR); discontinue 30 days after CR or after 90 days of treatment, whichever occurs first.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with arsenic trioxide:</i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses until &lt;5% blasts in marrow and no abnormal promyelocytes or complete remission, up to a maximum of 60 or 85 days; refer to protocol(s) for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16373661','lexi-content-ref-23841729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16373661','lexi-content-ref-23841729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with idarubicin:</i>
<b> Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses until complete hematologic remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17975017','lexi-content-ref-18664623','lexi-content-ref-20393132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17975017','lexi-content-ref-18664623','lexi-content-ref-20393132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with daunorubicin and cytarabine: </i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses until complete remission or 90 days (Powell 2010) or until complete hematologic remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17975017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17975017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with arsenic trioxide and gemtuzumab ozogamicin:</i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses until &lt;5% blasts in marrow and no abnormal promyelocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19075265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19075265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with gemtuzumab ozogamicin:</i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses until complete remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Consolidation therapy (off-label use):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with arsenic trioxide:</i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses days 1 to 14 every 28 days for 7 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16373661','lexi-content-ref-19075265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16373661','lexi-content-ref-19075265'])">Ref</a></span>) <b>or</b> for 2 weeks every 28 days for 7 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23841729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23841729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin with idarubicin/mitoxantrone:</i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses for 15 days each month for 3 months (in combination with idarubicin [courses 1 and 3] and mitoxantrone [course 2]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20644121','lexi-content-ref-20393132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20644121','lexi-content-ref-20393132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tretinoin and daunorubicin after arsenic trioxide: </i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses for 7 days of each cycle (in combination with daunorubicin for 2 cycles; begin after 2 arsenic trioxide consolidation cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20705755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20705755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Maintenance therapy (off-label use):</b></i>
<b>Oral: </b>45 mg/m<sup>2</sup>/day in 2 equally divided doses for 15 days every 3 months (in combination with mercaptopurine and methotrexate) for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17975017','lexi-content-ref-14576047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17975017','lexi-content-ref-14576047'])">Ref</a></span>) <b>or</b> 45 mg/m<sup>2</sup>/day in 2 equally divided doses for 7 days every other week (± mercaptopurine and methotrexate) for 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20705755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20705755'])">Ref</a></span>). <b>Note:</b> For non–high-risk patients (WBC ≤10,000/mm<sup>3</sup>) receiving chemotherapy-free therapy, maintenance therapy is not needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30803991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30803991'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990942"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988268"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment: Liver function tests &gt;5 × ULN: Consider temporarily withholding treatment. Most liver function test abnormalities will resolve without interruption of treatment or after completion of tretinoin therapy.</p></div>
<div class="block adr drugH1Div" id="F230396"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (23%), chest discomfort (32%), edema (29%), flushing (23%), hypertension (11%), hypotension (14%), peripheral edema (52%), phlebitis (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (14%), diaphoresis (20%), pruritus (20%), skin changes (14%), skin rash (54%), xeroderma (≤77%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (≤60%), hypertriglyceridemia (≤60%), weight gain (23%), weight loss (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (11%), abdominal pain (31%), anorexia (17%), constipation (17%), diarrhea (23%), dry mucous membranes (≤77%), dyspepsia (14%), gastrointestinal hemorrhage (34%), nausea (≤57%), stomatitis (26%), vomiting (≤57%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Differentiation syndrome (≤25%), disseminated intravascular coagulation (26%), hemorrhage (60%), leukocytosis (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (50% to 60%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (58%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (17%), confusion (11%), depression (14%), dizziness (20%), headache (86%), insomnia (14%), malaise (66%), pain (37%), paresthesia (17%), shivering (63%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (14%), ostealgia (77%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye disease (17%), visual disturbance (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (23%; including a feeling of ear fullness)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (60%), pleural effusion (20%), pneumonia (14%), rales (14%), respiratory insufficiency (26%), upper respiratory system symptoms (63%), wheezing (expiratory: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (83%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (3%), cardiomegaly (3%), cardiomyopathy (3%), heart failure (6%), heart murmur (3%), ischemia (3%), myocarditis (3%), pericarditis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (8%), pallor (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (3%), fluid volume disorder (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal ulcer (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign prostatic hypertrophy (3%), dysuria (9%), urinary frequency (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of the lymphatic system (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (3%), hepatitis (3%), hepatosplenomegaly (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (3%), agitation (9%), agnosia (3%), aphasia (3%), asterixis (3%), ataxia (3%), brain edema (3%), central nervous system depression (3%), cerebellar disorder (3%), cerebral hemorrhage (9%), cerebrovascular accident (3%), coma (3%), dementia (3%), drowsiness (3%), dysarthria (3%), encephalopathy (3%), facial nerve paralysis (3%), forgetfulness (3%), hallucination (6%), hemiplegia (3%), hyporeflexia (3%), hypothermia (3%), intracranial hypertension (9%), loss of consciousness (3%), seizure (3%), speech disturbance (slowing: 3%), tremor (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lower extremity weakness (3%), osteomyelitis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased pupillary reflex (3%), decreased visual acuity (6%), visual field defect (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (≤6%; may be irreversible)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (3%), flank pain (9%), renal tubular necrosis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (3%), laryngeal edema (3%), lower respiratory signs and symptoms (9%), pulmonary edema (3%), pulmonary hypertension (3%), pulmonary infiltrates (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Asthenia, fatigue</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thrombosis, atrioventricular block (Shih 2015), bradycardia (Karakatsanis 2014), venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (genital) (Yanamandra 2016), erythema nodosum, Sweet syndrome (van Der Vliet 2000), vasculitis of the skin</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Basophilia (Koike 1992), thrombocythemia (Aldapt 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Histamine release (hyperhistaminemia) (Koike 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myositis (van Der Vliet 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal infarction</p></div>
<div class="block coi drugH1Div" id="F230410"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to tretinoin, other retinoids, parabens, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy; breastfeeding; patients at risk of becoming pregnant who are unable to follow or comply with required contraceptive measures; concurrent use with vitamin A, tetracyclines, or other retinoids.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F230393"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Venous thrombosis and myocardial infarction (MI) have been reported in patients without risk factors for thrombosis or MI. The risk for thrombosis (arterial and venous) is increased during the first month of treatment. Use with caution with antifibrinolytic agents; thrombotic complications have been reported (rarely) with concomitant use.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause headache, malaise, and/or dizziness; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Differentiation syndrome: About 25% of patients with acute promyelocytic leukemia (APL) treated with tretinoin have experienced differentiation syndrome (formerly called retinoic-acid-APL [RA-APL] syndrome or APL differentiation syndrome), which is characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural or pericardial effusions, edema, and hepatic, renal, and/or multiorgan failure. Differentiation syndrome may be accompanied by impaired myocardial contractility and episodic hypotension. It has been observed with or without concomitant leukocytosis. Intubation and mechanical ventilation have been required in some cases due to progressive hypoxemia; fatalities due to multiorgan failure have occurred. Differentiation syndrome generally occurs during the first month of treatment, with some cases reported following the first dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Leukocytosis: During treatment, ~40% of patients will develop rapidly evolving leukocytosis. Patients who present with a high WBC at diagnosis (&gt;5,000/mm<sup>3</sup>) are at increased risk of further rapid increase in WBC. Rapidly evolving leukocytosis is associated with a higher risk of life-threatening complications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Up to 60% of patients experienced hypercholesterolemia or hypertriglyceridemia, which were reversible upon completion of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Liver function test abnormalities: Elevated liver function test results occur in 50% to 60% of patients during treatment. Most liver function test abnormalities will resolve without interruption of treatment or after therapy completion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting, visual disturbances, intracranial noises, or pulsate tinnitus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Do not interchange: Tretinoin (which is also known as all-<i>trans</i> retinoic acid, or ATRA) and isotretinoin may be confused; while both products may be used in cancer treatment, they are <b>not</b> interchangeable. Verify product prior to dispensing and administration to prevent medication errors.</p></div>
<div class="block foc drugH1Div" id="F230404"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F230389"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324024"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tretinoin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $37.35</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868491"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vesanoid: 10 mg [contains soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block exp drugH1Div" id="F8771505"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">Although the manufacturer does not recommend the use of the capsule contents to extemporaneously prepare a suspension of tretinoin (due to reports of low plasma levels) (Vesanoid data on file), there are limited case reports of use in patients who are unable to swallow the capsules whole. In a patient with a nasogastric (NG) tube, tretinoin capsules were cut open, with partial aspiration of the contents aspirated into a glass syringe. The residual capsule contents were mixed with soybean oil, aspirated into the syringe, and administered (Shaw 1995). Tretinoin capsules have also been mixed with sterile water (~20 mL) and heated in a water bath to melt the capsules and create an oily suspension for NG tube administration (Bargetzi 1996). A tretinoin 2.5 mg/mL slurry has been prepared using 10 mg tretinoin capsules, SWFI, and mineral oil; add six 10 mg tretinoin capsules to a 30 mL syringe, then add 16.5 mL SWFI, cap syringe securely, place in hazardous material bag, and place in warmer for 10 to 15 minutes to allow capsules to dissolve; transfer into a separate 35 mL enteral syringe containing 7.5 mL mineral oil and gently shake; use within 24 hours (Przybylski 2021).</p>
<div class="reference">Bargetzi MJ, Tichelli A, Gratwohl A, et al. Oral all-transretinoic acid administration in intubated patients with acute promyelocytic leukemia. <i>Schweiz Med Wochenschr</i>. 1996;126(45):1944-1945.<span class="pubmed-id">8946598</span></div>
<div class="reference">Przybylski DJ, Jared JR, Fallon MJ. Extemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia. <i>J Oncol Pharm Pract</i>. 2021;27(7):1779-1783. doi:10.1177/1078155221990091<span class="pubmed-id">33499747</span></div>
<div class="reference">Shaw PJ, Atkins MC, Nath CE, et al. ATRA administration in the critically ill patient. <i>Leukemia</i>. 1995;9(7):1288.<span class="pubmed-id">7630206</span></div>
<div class="reference">Vesanoid data on file, Roche Pharmaceuticals</div>
</div>
<div class="block admp drugH1Div" id="F52613963"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with a meal.</p>
<p style="text-indent:-2em;margin-left:4em;">For patients unable to swallow capsules, the following options may be considered and contents consumed within 1 hour: Poke a small hole in the capsule and patients may chew the capsule; capsules may be softened in water and then softened capsule chewed, swallowed, or mixed with jam/fatty food and then consumed; or puncture the capsule and squeeze contents onto a fatty food, mix, and consume (for this method, it is ideal to have patient suck on empty capsule to assist with getting full dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117210','lexi-content-ref-28767288','lexi-content-ref-24804005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117210','lexi-content-ref-28767288','lexi-content-ref-24804005'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">NG tube: In a patient with a nasogastric (NG) tube, tretinoin capsules were cut open, with partial aspiration of the contents into a glass syringe, the residual capsule contents were mixed with soy bean oil and aspirated into the same syringe and administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7630206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7630206'])">Ref</a></span>). Tretinoin capsules have also been mixed with sterile water (~20 mL) and heated in a water bath (37°C) to melt the capsules and create an oily suspension for NG tube administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8946598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8946598'])">Ref</a></span>). Tretinoin has also been administered sublingually by squeezing the capsule contents beneath the tongue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10332546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10332546'])">Ref</a></span>). For pediatric patients, some centers have suggested contents of capsule may be mixed with milk and administered NG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117210','lexi-content-ref-24804005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117210','lexi-content-ref-24804005'])">Ref</a></span>). Low plasma levels have been reported when contents of tretinoin capsules were administered directly through a feeding tube, although patient-specific impaired absorption may have been a contributing factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15114613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15114613'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F230407"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Tretinoin has also been administered sublingually by squeezing the capsule contents beneath the tongue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10332546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10332546'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Low plasma concentrations have been reported when tretinoin has been administered through a feeding tube, although patient-specific impaired absorption or a lack of excipient (eg, soybean oil) may have been a contributing factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15114613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15114613'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132846"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F230421"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store capsule at 20°C to 25°C (68°F to 77°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53569303"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Induction of remission in patients with acute promyelocytic leukemia (APL), French American British (FAB) classification M3 (including the M3 variant) characterized by t(15;17) translocation and/or PML/RARα gene presence (FDA approved in adults); has also been used in post consolidation and maintenance therapy in APL and combination therapy (with arsenic trioxide) for remission induction in APL.</p></div>
<div class="block mst drugH1Div" id="F16254058"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tretinoin may be confused with alitretinoin, ISOtretinoin, trientine</p>
<p style="text-indent:-2em;margin-left:4em;">Vesanoid may be confused with VESIcare</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tretinoin (which is also called all-<i>trans</i> retinoic acid, or ATRA) may be confused with isotretinoin; while both products may have uses in cancer treatment, they are <b>not</b> interchangeable.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F230441"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2E1 (weak)</p></div>
<div class="block dri drugH1Div" id="F230398"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antifibrinolytic Agents: Tretinoin (Systemic) may enhance the thrombogenic effect of Antifibrinolytic Agents.  Management: Concomitant use of antifibrinolytics and tretinoin is not recommended. If combined, monitor patients closely for any signs of thrombotic complications.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tretinoin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Tretinoin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Retinoic Acid Derivatives may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Progestins (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives. Microdosed progesterone-only preparations (ie, minipills that do not contain estrogen) are considered an inadequate method of contraception.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F230422"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Absorption of retinoids has been shown to be enhanced when taken with food. Management: Administer with food.</p></div>
<div class="block dic drugH1Div" id="F230414"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Capsule contains soybean oil.</p></div>
<div class="block rep_considerations drugH1Div" id="F53632812"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">A serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL must be done within 1 week prior to the institution of tretinoin capsules. When possible, tretinoin capsules should be delayed until a negative result is obtained. If a delay is not possible, the patient should be placed on two reliable forms of contraception. Pregnancy testing and contraception counseling should be repeated monthly throughout the period of tretinoin capsules treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Two reliable forms of contraception must be used simultaneously during therapy and for 1 month following discontinuation of tretinoin. Contraception must be used even when there is a history of infertility or menopause, unless a hysterectomy has been performed. Microdosed progesterone products ("minipill") may provide inadequate pregnancy protection.</p>
<p style="text-indent:0em;margin-top:2em;">If tretinoin capsules are the best available treatment for a patient who can become pregnant, it must be assured that the patient has received full information and warnings of the risk to the fetus if pregnancy were to occur during tretinoin therapy and of the risk of possible contraception failure.</p></div>
<div class="block pri drugH1Div" id="F230413"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tretinoin was detected in the serum of a neonate at birth following maternal use of standard doses during pregnancy (Takitani 2005).</p>
<p style="text-indent:0em;margin-top:2em;">There is a high risk that a severely deformed infant will result if tretinoin capsules are administered during pregnancy. Major fetal abnormalities and spontaneous abortions have been reported with other retinoids; some of these abnormalities were fatal. Birth defects associated with exposure to retinoids include facial dysmorphia, cleft palate, eye abnormalities and abnormalities of the central nervous system, cardiovascular system, musculoskeletal system, and parathyroid hormone deficiencies<i>.</i> All exposed fetuses have the potential to be affected.</p>
<p style="text-indent:0em;margin-top:2em;">Use in humans for the treatment of acute promyelocytic leukemia (APL) is limited and exposure occurred after the first trimester in most cases (Santolaria 2020). If the clinical condition of a patient presenting with APL during pregnancy warrants immediate treatment, tretinoin use should be avoided in the first trimester; treatment with tretinoin may be considered in the second and third trimester with careful fetal monitoring, including cardiac monitoring (ELN [Sanz 2019]). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team that includes an obstetrician, a neonatologist, and the oncology team (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53569304"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Bone marrow cytology to confirm t(15;17) translocation or the presence of the PML/RARα fusion protein (do not withhold treatment initiation for results); monitor CBC with differential, coagulation profile, liver function test results, and triglyceride and cholesterol levels frequently; monitor closely for signs of acute promyelocytic leukemia differentiation syndrome (eg, monitor volume status, pulmonary status, temperature, respiration).</p></div>
<div class="block pha drugH1Div" id="F230392"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tretinoin appears to bind one or more nuclear receptors and decreases proliferation and induces differentiation of APL cells; initially produces maturation of primitive promyelocytes and repopulates the marrow and peripheral blood with normal hematopoietic cells to achieve complete remission.</p></div>
<div class="block phk drugH1Div" id="F230409"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;">
<b>Note: </b>Reported pediatric values similar to adult (Smith 1992; Takitani 2004)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;95%, predominantly to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP; primary metabolite: 4-oxo-all-<i>trans</i>-retinoic acid; displays autometabolism </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: Parent drug: 0.5 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1 to 2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (63%); feces (30%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F230415"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Di wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ca atra 10 | Vesanoid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tretin | Vesanoid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amilogen | Vesanoid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid | Vesanoid farma mondo | Vesanoid specific | Vesanoid unimedic</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Oratane | Vesanoid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Vesanoid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.2020">
<a name="HazardousDrugs.2020"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117210">
<a name="24117210"></a>Abla O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukaemia. <i>Br J Haematol</i>. 2014;164(1):24-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/24117210/pubmed" id="24117210" target="_blank">24117210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975017">
<a name="17975017"></a>Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i>. 2008;111(3):1078-1084. doi:10.1182/blood-2007-07-099978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/17975017/pubmed" id="17975017" target="_blank">17975017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29633731">
<a name="29633731"></a>Aldapt MB, Kassem N, Al-Okka R, et al. Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment. <i>Acta Biomed</i>. 2018;89(3-S):33-37. doi:10.23750/abm.v89i3-S.7218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/29633731/pubmed" id="29633731" target="_blank">29633731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8946598">
<a name="8946598"></a>Bargetzi MJ, Tichelli A, Gratwohl A, et al, “Oral All-Transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia,” <i>Schweiz Med Wochenschr</i>, 1996, 126(45):1944-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/8946598/pubmed" id="8946598" target="_blank">8946598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8656678">
<a name="8656678"></a>Chen GQ, Shen ZX, Wu F, et al, “Pharmacokinetics and Efficacy of Low-Dose All-<i>trans</i> Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia,” <i>Leukemia</i>, 1996, 10(5):825-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/8656678/pubmed" id="8656678" target="_blank">8656678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15084614">
<a name="15084614"></a>de Botton S, Coiteux V, Chevret S, et al, "Outcome of Childhood Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid and Chemotherapy," <i>J Clin Oncol</i>, 2004, 22(8):1404-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/15084614/pubmed" id="15084614" target="_blank">15084614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16373661">
<a name="16373661"></a>Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i>. 2006;107(9):3469-3473. doi:10.1182/blood-2005-10-4006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/16373661/pubmed" id="16373661" target="_blank">16373661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010830">
<a name="12010830"></a>Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. <i>Blood</i>. 2002;99(11):4222-4224. doi:10.1182/blood-2001-12-0174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/12010830/pubmed" id="12010830" target="_blank">12010830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19743516">
<a name="19743516"></a>Gregory J, Kim H, Alonzo T, et al, “Treatment of Children With Acute Promyelocytic Leukemia: Results of the First North American Intergroup Trial INT0129,” <i>Pediatr Blood Cancer</i>, 2009, 53(6):1005-1010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/19743516/pubmed" id="19743516" target="_blank">19743516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32171751">
<a name="32171751"></a>Heuser M, Ofran Y, Boissel N, et al; ESMO Guidelines Committee. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2020;31(6):697-712. doi:10.1016/j.annonc.2020.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/32171751/pubmed" id="32171751" target="_blank">32171751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24659681">
<a name="24659681"></a>Karakatsanis S, Vardaka M, Giannoulia P, Apostolidis J, Delimpasi S. Bradycardia during induction therapy with all-trans retinoic acid (ATRA). <i>J BUON</i>. 2014;19(1):315.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/24659681/pubmed" id="24659681" target="_blank">24659681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1625712">
<a name="1625712"></a>Koike T, Tatewaki W, Aoki A, et al. Brief report: severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). <i>N Engl J Med</i>. 1992;327(6):385-7. doi:10.1056/NEJM199208063270604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/1625712/pubmed" id="1625712" target="_blank">1625712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10332546">
<a name="10332546"></a>Kueh YK, Liew PP, Ho PC, et al, “Sublingual Administration of All-<i>Trans</i>-Retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia,” <i>Ann Pharmacother</i>, 1999, 33(4):503-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/10332546/pubmed" id="10332546" target="_blank">10332546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8336187">
<a name="8336187"></a>Kurzrock R, Estey E, and Talpaz M, “All-<i>trans</i> Retinoic Acid: Tolerance and Biologic Effects in Myelodysplastic Syndrome,” <i>J Clin Oncol</i>, 1993, 11(8):1489-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/8336187/pubmed" id="8336187" target="_blank">8336187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28767288">
<a name="28767288"></a>Kutny MA, Alonzo TA, Gerbing RB, et al. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. <i>J Clin Oncol</i>. 2017;35(26):3021-3029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/28767288/pubmed" id="28767288" target="_blank">28767288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9031084">
<a name="9031084"></a>Lazzarino M, Regazzi MB, and Corso A, “Clinical Relevance of All-<i>trans</i> Retinoic Acid Pharmacokinetics and Its Modulation in Acute Promyelocytic Leukemia,” <i>Leuk Lymphoma</i>, 1996, 23(5-6):539-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/9031084/pubmed" id="9031084" target="_blank">9031084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23841729">
<a name="23841729"></a>Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>N Engl J Med</i>. 2013;369(2):111-121. doi:10.1056/NEJMoa1300874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/23841729/pubmed" id="23841729" target="_blank">23841729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20644121">
<a name="20644121"></a>Lo-Coco F, Avvisati G, Vignetti M, et al; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i>. 2010;116(17):3171-3179. doi:10.1182/blood-2010-03-276196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/20644121/pubmed" id="20644121" target="_blank">20644121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11529468">
<a name="11529468"></a>Mann G, Reinhardt D, Ritter J, et al, "Treatment With All-trans Retinoic Acid in Acute Promyelocytic Leukemia Reduces Early Deaths in Children," <i>Ann Hematol</i>, 2001, 80(7):417-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/11529468/pubmed" id="11529468" target="_blank">11529468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18945964">
<a name="18945964"></a>Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i>. 2009;113(4):775-783. doi:10.1182/blood-2008-07-168617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/18945964/pubmed" id="18945964" target="_blank">18945964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1559217">
<a name="1559217"></a>Muindi JR, Frankel SR, Huselton C, et al, “Clinical Pharmacology of Oral All-<i>trans</i> Retinoic Acid in Patients With Acute Promyelocytic Leukemia,” <i>Cancer Res</i>, 1992, 52(8):2138-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/1559217/pubmed" id="1559217" target="_blank">1559217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234524">
<a name="16234524"></a>Ortega JJ, Madero L, Martin G, et al, “Treatment With All-<i>Trans</i> Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,” <i>J Clin Oncol</i>, 2005, 23(30):7632-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/16234524/pubmed" id="16234524" target="_blank">16234524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20705755">
<a name="20705755"></a>Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i>. 2010;116(19):3751-3757. doi:10.1182/blood-2010-02-269621<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/20705755/pubmed" id="20705755" target="_blank">20705755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33499747">
<a name="33499747"></a>Przybylski DJ, Jared JR, Fallon MJ. Extemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia. <i>J Oncol Pharm Pract</i>. 2021;27(7):1779-1783. doi:10.1177/1078155221990091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/33499747/pubmed" id="33499747" target="_blank">33499747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19075265">
<a name="19075265"></a>Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. <i>J Clin Oncol</i>. 2009;27(4):504-510. doi:10.1200/JCO.2008.18.6130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/19075265/pubmed" id="19075265" target="_blank">19075265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21364078">
<a name="21364078"></a>Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. <i>J Oncol Pharm Pract</i>. 2012;18(1):109-114. doi:10.1177/1078155211399163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/21364078/pubmed" id="21364078" target="_blank">21364078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32295152">
<a name="32295152"></a>Santolaria A, Perales A, Montesinos P, Sanz MA. Acute promyelocytic leukemia during pregnancy: a systematic review of the literature. <i>Cancers (Basel)</i>. 2020;12(4):968. doi:10.3390/cancers12040968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/32295152/pubmed" id="32295152" target="_blank">32295152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30803991">
<a name="30803991"></a>Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i>. 2019;133(15):1630-1643. doi:10.1182/blood-2019-01-894980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/30803991/pubmed" id="30803991" target="_blank">30803991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14576047">
<a name="14576047"></a>Sanz MA, Martin G, Gonzalez M, et al; Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i>. 2004;103(4):1237-1243. doi:10.1182/blood-2003-07-2462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/14576047/pubmed" id="14576047" target="_blank">14576047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20393132">
<a name="20393132"></a>Sanz MA, Montesinos P, Rayón C, et al; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i>. 2010;115(25):5137-5146. doi:10.1182/blood-2010-01-266007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/20393132/pubmed" id="20393132" target="_blank">20393132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18664623">
<a name="18664623"></a>Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i>. 2008;112(8):3130-3134. doi:10.1182/blood-2008-05-159632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/18664623/pubmed" id="18664623" target="_blank">18664623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7630206">
<a name="7630206"></a>Shaw PJ, Atkins MC, Nath CE, et al, ”ATRA Administration in the Critically Ill Patient,” <i>Leukemia</i>, 1995, 9(7):1288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/7630206/pubmed" id="7630206" target="_blank">7630206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25726499">
<a name="25726499"></a>Shih CH, Wu HB. All-trans retinoic acid-induced, life-threatening complete atrioventricular block. <i>J Chin Med Assoc</i>. 2015;78(5):316-319. doi:10.1016/j.jcma.2014.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/25726499/pubmed" id="25726499" target="_blank">25726499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1403049">
<a name="1403049"></a>Smith MA, Adamson PC, Balis FM, et al, “Phase I and Pharmacokinetic Evaluation of All-<i>trans</i>-Retinoic Acid in Pediatric Patients With Cancer,” <i>J Clin Oncol</i>, 1992, 10(11):1666-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/1403049/pubmed" id="1403049" target="_blank">1403049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31410848">
<a name="31410848"></a>Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. <i>Br J Haematol</i>. 2019;187(2):157-162. doi:10.1111/bjh.16151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/31410848/pubmed" id="31410848" target="_blank">31410848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16227682">
<a name="16227682"></a>Takitani K, Hino N, Terada Y, et al. Plasma all-trans retinoic acid level in neonates of mothers with acute promyelocytic leukemia. <i>Acta Haematol</i>. 2005;114(3):167-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/16227682/pubmed" id="16227682" target="_blank">16227682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16838336">
<a name="16838336"></a>Takitani K, Koh M, Inoue A, et al, "Pharmacokinetics of All-<i>Trans</i> Retinoic Acid in Adults and Children With Acute Promyelocytic Leukemia," <i>Am J Hematol</i>, 2006, 81(9):720-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/16838336/pubmed" id="16838336" target="_blank">16838336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15114613">
<a name="15114613"></a>Takitani K, Nakao Y, Kosada Y, et al, “Low Plasma Levels of All-<i>Trans</i> Retinoic Acid After Feeding Tube Administration for Acute Promyelocytic Leukemia,” <i>Am J Hematol</i>, 2004, 76(1):97-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/15114613/pubmed" id="15114613" target="_blank">15114613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15677559">
<a name="15677559"></a>Testi AM, Biondi A, Lo Coco F, et al, “GIMEMA_AIEOPAIDA Protocol for the Treatment of Newly Diagnosed Acute Promyelocutic Leukemia (APL) in Children,” <i>Blood</i>, 2005, 106(2): 447-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/15677559/pubmed" id="15677559" target="_blank">15677559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24804005">
<a name="24804005"></a>Testi AM, D'Angiò M, Locatelli F, Pession A, Lo Coco F. Acute promyelocytic leukemia (APL): comparison between children and adults. <i>Mediterr J Hematol Infect Dis</i>. 2014;6(1):e2014032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/24804005/pubmed" id="24804005" target="_blank">24804005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tretinoin.1">
<a name="Tretinoin.1"></a>Tretinoin [prescribing information]. Columbus, OH: American Health Packaging; February 2013</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tretinoin.2">
<a name="Tretinoin.2"></a>Tretinoin [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tretinoin.3">
<a name="Tretinoin.3"></a>Tretinoin capsules [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10629576">
<a name="10629576"></a>van Der Vliet HJ, Roberson AE, Hogan MC, et al. All-trans-retinoic acid-induced myositis: a description of two patients. <i>Am J Hematol</i>. 2000;63(2):94-98. doi:10.1002/(sici)1096-8652(200002)63:2&lt;94::aid-ajh7&gt;3.0.co;2-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/10629576/pubmed" id="10629576" target="_blank">10629576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vesanoid.1">
<a name="Vesanoid.1"></a>Vesanoid (tretinoin) [prescribing information]. Nutley, NJ: Roche Laboratories; October 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vesanoid.2">
<a name="Vesanoid.2"></a>Vesanoid (tretinoin) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26791116">
<a name="26791116"></a>Yanamandra U, Khadwal A, Saikia UN, Malhotra P. Genital vasculitis secondary to all-trans-retinoic-acid. <i>BMJ Case Rep</i>. 2016;2016:bcr2015212205. doi:10.1136/bcr-2015-212205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/all-trans-retinoic-acid-systemic-tretinoin-pediatric-drug-information/abstract-text/26791116/pubmed" id="26791116" target="_blank">26791116</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13099 Version 382.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
